1. AbBcn S.L. your partner in antibodies http://antibodybcn.eu

2. 2004 Distribution of good quality antibodies for research 2010 Own manufacturing facilities Diagnostic Kits distributor EU projects 2011 2012 Bigger laboratory Company description: history

3. Company description: main areas Distribution Custom services Innovative projects More than 30 brands worlwide Distribution in Spain, Chile and Argentina. Reactives for research Antibody Production Immunoassays optimization Diagnostic projects Health, agrofood, biosensors

4. Company description: Staff AbBcn S.L. President José Vicente Costa, Bch AbBcn S.L. President José Vicente Costa, Bch R & D Director Monica Jara, Ph.D. R & D Director Monica Jara, Ph.D. Marketing & Sales, Mireia Martin, Bch. Marketing & Sales, Mireia Martin, Bch. Finance & Administration, Pilar Juarez, Bch Finance & Administration, Pilar Juarez, Bch Laboratory Carlota Bardina, Ph.D. Laura Teixidó, Ph.D. Albert Sandoval Laboratory Carlota Bardina, Ph.D. Laura Teixidó, Ph.D. Albert Sandoval Marketing assistant, Victor Juarez, Bch Marketing assistant, Victor Juarez, Bch Project Coordinator, Marina Azor, Bch. Project Coordinator, Marina Azor, Bch. General Manager Advisor Elisabeth Lopez Advisor Elisabeth Lopez

5. Custom services

6. Laboratory Services: Antibody Production Synthesis of antigens (peptides and recombinant proteins) Scientific advice for improving your immunoassay Monoclonal Antibody Production Hybridoma production in 20 weeks Policlonal Antibody Production: goat, rabbit, chicken, mouse Selecting the best antibody (ELISA, flow cytometry, Western Blot, Immuno Fluorescence, Isoelectric point, Biacore Analysis, Epitope mapping…) Selecting the best clone (fast grow, best secretor of antibody…) Antibody production from 0,1 mg to 1 g.

7. Projects

8. CallTitleAcronymYearPartnersState PETRIDetection of antibiotics in animal productionMabpa2007-2009UdL-UABFinished PETRIDevelopment and characterization of monoclonal antibodies for research use Biomedmab2007-2009UdLFinished PETRIMuscle biomarkers for the diagnosis of muscular injury Myomabs2009-2011IDIBAPSFinished TRACEDevelopment of monoclonal antibodies for monitoring the pharmacological treatment of psychiatric patients Psicofarma2009Parc TauliDenied TRACEDetection of microRNAs involved in glioblastoma resistance to TRAIL miRNA2010-2011UABFinished NUCLIResearch and development of a system for the rapid detection of microorganisms. Famidet2010AbBiotics RAL Denied INNPACTODevelopment of new peptide tagsEPITAG2010-2013IBB CSIC Immunostep Ongoing Research Projects

9. CallTitleAcronymYearPartnersState 7PM“Early detection of HIV-1 using ultra- sensitive, rapid capacitive biosensor”, CAPHIV2011-2013MFKK, LIONEX LUNDS PHENOSYSTEM S CAPSENZE Ongoing INNPACTOInnovation and development of portable high detection efficiency Biological Optics INNBIOD2011-2014LASING CSIC- CIN2, UPM, BIOFTALMIK Ongoing 7PMInfectious disease diagnostics For LOW resource settings INFLOW2012ICRM-CNR, ICN, Dia. Pro srl, MerceneLab Denied 7PMMicrofluidic platform integrating plasmonic nanodevices enabling high throughput screening of tumor cells CELL10002012CMGBR, Mimetas, UMG Denied EurotransbioFast detection of bacterial contamination on cosmetic products Cosmedet2013ImicroQ GOVA Cancelled

10. CallTitleAcronymYearPartnersState EurotransbioA novel KIT for Predicting Plant Seed PredicSeed2013Ninsar Microcoat Max Planck Ongoing EurekaDetection of Bacteria causing Pneumonia in an automated multianalyte point of care device PneuPOC2013ArcDiaApproved, but since the Spanish government was unable to provide finance to it, it was cancelled. Research Projects

11. Current research projects Title: “Development of new peptide tags” (EpiTag) Participants: AbBcn S.L. (Project leader), IBMB (Institut de Biologia Molecular de Barcelona), IRB (Institut de Recerca de Barcelona), Immunostep S.L. Coordinator and owner INNPACTO 2010 Target definition In vivo tests Monoclonal production Antibodies testing Final product Tag 5 Tag 6 Tag 10

12. Current research projects INNPACTO 2011 Title: “Innovation and development of portable high detection efficiency Biological Optics” (Innbiod) Participants: LASING S.A., AbBcn S.L., CSIC-CENTRO DE INVESTIGACION EN NANOCIENCIA Y NANOTECNOLOGIA (CIN2) CSIC-CIN2, UPM (Universitat Pública de Madrid), BIOFTALMIK S.L. Participant Protein production Monoclonal production Antibodies testing Final product Biomarker 1 Biomarker 2 Biomarker 3 Biomarker 4 Biomarker 5 Biomarker 6

13. Current European research projects FP7 2010 Title: “Early detection of HIV-1 using ultra-sensitive, rapid capacitive biosensor”, CAPHIV. Participants: MFKK, LIONEX GMBH, LUNDS UNIVERSITET, PHENOSYSTEMS SA, CAPSENZE, ABBCN S.L Participant Commercial antibodies report Monoclonal antibody production Mab testing on the device DEMO project AbBcn

14. What we look for

15. Selection of biomarker, assay, instrument, and consumable and usability are the main items when starting a project for development of IVD kits Partnership for IVD kits development Development of the consumable and its future commercial scale manufacture are key elements very often neglected when starting a project development as well as for manufacture. Biomarker producer should participate since the very beginning of the IVD kit in: Establishment of kit specifications Acceptance/rejection criteria for each lot produced Development of QC tests for the antibody to assure quality of final kit Scale up forecasts, production scheduling, scale up complications Close and trustful communication is essential to obtain a reliable IVD kit Biomarker relevance is often neglected. Better markers should be prioritized over better devices.

16. Examples of work packages flow Antibody development, specific for selected biosensor Support in kit specifications establishment Partner 1 Partner 2 Antibody immobilization Gold nanoparticles Assembled monolayer Affinity proteins Prolinker Biosensor Capacitive Photonic Partner 3 and 4 Assembly and testing validation Proof of concept Comparison vs traditional methods Scale up

17. IVD Manufacturer Role Assay performance Marketing Sales Antibody development, specific for selected biosensor Support in kit specifications stablishment Regulatory activities (through ELM Pharma) Coordination (through ELM Pharma) AntibodyBcn Role

18. IVD kits development Companies interested in high quality custom made antibodies market Partnership in projects related to early detection using antibodies AbBcn has experience in Health, Agrofood, & Environment Conclusion AbBcn is interested in Biotech market related to: And so can assist and participate in

19. IVD Manufacturer Role Assay performance Marketing Sales Antibody development, specific for selected biosensor Support in kit specifications stablishment Regulatory activities (through ELM Pharma) Coordination (through ELM Pharma) AntibodyBcn Role

20. Tuberculosis IVD: seeking for partner Project  Tuberculosis IVD based in magnetic turbidimetry  Quick (less 15 min) and cheap, alternative to PCR (expensive)  User friendly for non specialists  False negative <20% (currently available 42-47%)  Detection limit 10 times less than Latex-Enhanced Immunoturbidimetry (LEI)  Possibility to recover sample for further culture Participants Biosensor: Clinical validation Antibody: Development: Project status-Budget-Duration Project is ready to start. Duration: 3 years 300000 € aprox

21. Thank you www.antibodybcn.eu